We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.
Moderna cuts 2025 sales forecast by $1 billion due to weak RSV and COVID-19 vaccine demand, prompting strategic shifts and cost reductions.
Eli Lilly's $2.5 billion acquisition of Scorpion Therapeutics marks a significant expansion in its oncology portfolio, reflecting a focus on innovative cancer therapies.
The healthcare sector anticipates a resurgence in M&A activity by 2025, bolstered by improved economic conditions and reduced regulatory hurdles.
Metsera aims to go public on Nasdaq, capitalizing on strong equity markets and growing demand for weight-loss solutions, backed by ARCH Venture Partners.
Gilead Sciences partners with LEO Pharma to develop STAT6-based therapies for inflammatory diseases, aiming to enhance patient care with new treatment options.
Biogen plans to acquire Sage Therapeutics, boosting Sage's stock by 34%. This move underscores key market shifts in pharmaceuticals.
Virta Health reports a 60% revenue increase in 2024 by providing nutrition programs as an alternative to costly drugs, appealing to employers focused on sustainable solutions.
Walgreens reports better-than-expected earnings with strategic moves boosting sales, despite net losses and ongoing challenges.
Discover how Eli Lilly's Zepbound received Medicare coverage for sleep apnea, offering new treatment possibilities for millions of Americans.
Walgreens Boots Alliance faces analyst skepticism ahead of its earnings report, with mixed ratings and potential acquisition talks casting uncertainty over its stock performance.
Novo Nordisk shares rise post-UBS upgrade, reflecting positive sentiment in the weight-loss drug market despite recent challenges.
Roche enhances its biopharmaceutical capabilities with the acquisition of Poseida Therapeutics, securing a stronger position in the gene therapy market.
632
